Replies to post #168108 on Biotech Values

[genisi]

there is some compelling data for competing companies expected at AASLD. In particular GILD BMY and perhaps MRK may have early data on viable regimens without ribavirin.

I am quite certain you don't need the word 'perhaps' in conjunction with MRK's C-WORTHY (MK-5172 in combination with MK-8742 ± ribavirin) Study data.

http://www.natap.org/2013/HCV/100313_01.htm